Background: Disease-modifying therapy (DMT) delays disease progression and improves quality of life for patients with multiple sclerosis (MS), but adherence to DMT is often suboptimal. Vanderbilt Specialty Pharmacy (VSP) embeds pharmacists within an outpatient MS clinic to provide medication management and address barriers to adherence.
Objective: We evaluated rates and predictors of adherence to DMT among patients with MS at an integrated specialty pharmacy.
Methods: We included patients with MS who filled ≥3 DMT prescriptions from VSP during the study period. Adherence was defined as medication possession ratio (MPR) or proportion of days covered (PDC) ≥0.8. Reasons for nonadherence were collected from pharmacy claims and electronic medical records.
Results: The study included 653 patients. Average MPR and PDC were 0.93 and 0.94, respectively. Eighty-eight percent of patients achieved MPR ≥0.8; 89% achieved PDC ≥0.8. Using financial assistance and having $0 out-of-pocket cost were associated with higher odds of achieving MPR and PDC ≥0.8 ( < .05). Of the 12% of patients who were nonadherent, most were unreachable for refills.
Conclusions: Ensuring financial assistance and low out-of-pocket costs are associated with high adherence to DMT within an integrated specialty clinic, but more work is needed to address adherence in unreachable patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0897190018824821 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.
Ann Clin Transl Neurol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Objective: To investigate retinal layer thinning as a biomarker of disease-modifying treatment (DMT) effects in relapsing multiple sclerosis (RMS).
Methods: From an ongoing prospective observational study, we included patients with RMS, who (i) had an optical coherence tomography (OCT) scan within 6 to 12 months after DMT start (rebaseline) and ≥1 follow-up OCT ≥12 months after rebaseline and (ii) adhered to DMT during follow-up. Differences between DMT in thinning of peripapillary-retinal-nerve-fiber-layer (pRNFL) and macular ganglion cell-plus-inner plexiform-layer (GCIPL) were analyzed using mixed-effects linear regression.
Azathioprine for people with multiple sclerosis.
Cochrane Database Syst Rev
December 2024
Scientific Director's Office, Carlo Besta Foundation and Neurological Institute, Milan, Italy.
Background: Multiple sclerosis (MS) is an immune-mediated, chronic, inflammatory demyelinating disease of the central nervous system, impacting around 2.8 million people worldwide. Characterised by recurrent relapses or progression, or both, it represents a substantial global health burden, affecting people, predominantly women, at a young age (the mean age of diagnosis is 32 years).
View Article and Find Full Text PDFAppointment non-attendance is associated with disease modifying therapy persistence the following year.
Mult Scler Relat Disord
December 2024
Multiple Sclerosis Center of Excellence West, Veterans Affairs, 1660 South Columbian Way, Seattle, WA 98108, USA; Rehabilitation Care Service, VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA; Department of Rehabilitation Medicine, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA; Department of Epidemiology, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA.
Background: It is recommended that healthcare providers and persons with multiple sclerosis (MS) have discussions prior to discontinuing a disease modifying therapy (DMT). However, if these appointments missed, either as a no show (NS) or short-notice cancellation (SNC), these discussions do not take place and may result in premature discontinuation. This study aimed to explore whether appointment non-attendance was predictive of DMT persistence the following year.
View Article and Find Full Text PDFReal-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis.
Mult Scler Relat Disord
November 2024
Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA.
Article Synopsis
- - The study evaluates how well patients stick to their prescribed treatments (persistence and adherence) for the multiple sclerosis medication Ofatumumab (OMB) compared to oral and other self-injectable disease-modifying therapies (DMTs) in a real-world setting from August 2020 to November 2021.
- - Researchers used a retrospective cohort design involving over 11,000 patients, analyzing treatment adherence through measures like the proportion of days covered (PDC) and persistence defined as the time until treatment discontinuation or switch.
- - Results identified two specific patient groups: one using OMB and the other using oral DMTs, enabling a comparison of treatment persistence and adherence between the different therapy types within the study's defined cohorts
Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs.
Basic Clin Neurosci
November 2023
Department of Clinical Pharmacy, Rational Use of Drugs Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.
Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!